Baird’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Baird’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-14,409	Closed	-$896K	–	1354
2014 Q4	$896K	Sell	14,409 -5,343	-27%	-$305K	0.01%	760
2014 Q3	$1.03M	Buy	+19,752	New	+$1.01M	0.01%	647
2013 Q4	–	Sell	-28,158	Closed	-$1.21M	–	1149
2013 Q3	$1.21M	Buy	28,158 +7,293	+35%	+$295K	0.02%	538
2013 Q2	$725K	Buy	+20,865	New	+$733K	0.01%	654

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Baird's XBI Position: Q1 2015 in Review

Baird sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2015, closing a stake of 14,409 shares — an estimated $896K sold.

Baird first reported a position in XBI in Q2 2013 and held it in 4 quarters. The position peaked at $1.21M in Q3 2013. 180 funds tracked by Wall St. Rank hold XBI as of Q1 2015.

Baird reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2015 after selling out during the quarter.
Baird sold 14,409 State Street SPDR S&P Biotech ETF shares in Q1 2015, an estimated $896K.
Baird first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and held it in 4 quarters.
Baird's State Street SPDR S&P Biotech ETF position peaked at $1.21M in Q3 2013.
180 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.